Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rocco Giannicola

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The Lancet. Oncology|June 2, 2022
Abemaciclib for malignant pleural mesotheliomaValerio Nardone, Camillo Porta, Rocco Giannicola, et al.
Immunotherapy|December 24, 2019
Could PD-1/PDL1 immune checkpoints be linked to HLA signature?Pierpaolo Correale, Rita E Saladino, Valerio Nardone, et al.
Frontiers in Immunology|January 9, 2019
How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other StrategiesValerio Nardone, Pierpaolo Pastina, Rocco Giannicola, et al.
Translational Lung Cancer Research|November 19, 2020
On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancerPierpaolo Correale, Rocco Giannicola, Rita Emilena Saladino, et al.
International Journal of Molecular Sciences|August 27, 2021
CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for AutophagyValerio Nardone, Marcella Barbarino, Antonio Angrisani, et al.
Frontiers in Oncology|July 1, 2021
Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint BlockadeValerio Nardone, Rocco Giannicola, Giovanna Bianco, et al.
Basic Research in Cardiology|September 3, 2024
Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patientsGiuseppe Panuccio, Pierpaolo Correale, Maria d'Apolito, et al.
Molecular and Clinical Oncology|July 11, 2019
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumabRocco Giannicola, Graziella D'Arrigo, Cirino Botta, et al.
International Journal of Molecular Sciences|July 2, 2021
Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case ReportCirino Botta, Rita Maria Agostino, Vincenzo Dattola, et al.
Oncotarget|May 15, 2018
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccinePierpaolo Correale, Cirino Botta, Nicoletta Staropoli, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Lancet. Oncology|June 2, 2022
Abemaciclib for malignant pleural mesotheliomaValerio Nardone, Camillo Porta, Rocco Giannicola, et al.
Immunotherapy|December 24, 2019
Could PD-1/PDL1 immune checkpoints be linked to HLA signature?Pierpaolo Correale, Rita E Saladino, Valerio Nardone, et al.
Frontiers in Immunology|January 9, 2019
How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other StrategiesValerio Nardone, Pierpaolo Pastina, Rocco Giannicola, et al.
Translational Lung Cancer Research|November 19, 2020
On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancerPierpaolo Correale, Rocco Giannicola, Rita Emilena Saladino, et al.
International Journal of Molecular Sciences|August 27, 2021
CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for AutophagyValerio Nardone, Marcella Barbarino, Antonio Angrisani, et al.
Frontiers in Oncology|July 1, 2021
Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint BlockadeValerio Nardone, Rocco Giannicola, Giovanna Bianco, et al.
Basic Research in Cardiology|September 3, 2024
Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patientsGiuseppe Panuccio, Pierpaolo Correale, Maria d'Apolito, et al.
Molecular and Clinical Oncology|July 11, 2019
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumabRocco Giannicola, Graziella D'Arrigo, Cirino Botta, et al.
International Journal of Molecular Sciences|July 2, 2021
Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case ReportCirino Botta, Rita Maria Agostino, Vincenzo Dattola, et al.
Oncotarget|May 15, 2018
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccinePierpaolo Correale, Cirino Botta, Nicoletta Staropoli, et al.
Pageof 2